SafeStitch Medical Completes Merger with TransEnterix

$30 Million Financing Raised from Existing TransEnterix and SafeStitch Medical Stockholders Combined Company to be Renamed TransEnterix [dropcap2]M[/dropcap2]IAMI, FL RESEARCH TRIANGLE, N.C.–(BUSINESS WIRE)–SafeStitch Medical, Inc. (OTCBB: SFES) and TransEnterix, Inc., a privately-held company, today announced that they have closed SafeStitch’s previously announced acquisition of TransEnterix. The combined company is expected to be renamed TransEnterix, subject to stockholder approval, and headquartered …

SafeStitch Medical Announces Definitive Agreement to Merge with TransEnterix

MIAMI, FL and RESEARCH TRIANGLE, N.C., August 14, 2013 – SafeStitch Medical, Inc. (OTCBB: SFES), today announced that it has entered into a definitive agreement to merge with TransEnterix, Inc., a privately-held, medical device company with advanced technology in the use of flexible devices and robotics for minimally invasive surgery. Commenting on the merger, Dr. Jane Hsiao, Chairwoman of SafeStitch …

Medical device startup raises $13.1 million

By David Ranii — dranii@newsobserver.com [dropcap2]M[/dropcap2]edical device startup NeuroTronik, which was spun out of a Chapel Hill business accelerator just 11 months ago, has raised its first round of outside funding: $13.1 million that is earmarked for continued development of a system to treat heart failure. “This has the potential to really be one of the biggest device companies to …

TransEnterix Secures $55 Million in Financing

“We are pleased with the confidence our distinguished investors have expressed in the TransEnterix team, our technology and the potential it offers for completely changing how laparoscopic surgeries are performed.” Todd M. Pope, President, CEO TransEnterix, Inc. RESEARCH TRIANGLE PARK, N.C. – (October 7, 2009) TransEnterix Inc. has secured $55 million in a second round of institutional financing, paving the …

TransEnterix Unveils Revolutionary Single-Port SPIDER™ System at SLS

“It was clear to us that medical experts in the field are excited about this game-changing technology that could improve the effectiveness of patient care.” Todd M. Pope, President, CEO TransEnterix, Inc. RESEARCH TRIANGLE PARK, N.C. – (September 17, 2009) Officials at TransEnterix introduced the company’s revolutionary single-port, multi-channel laparoscopic SPIDER™ System at the Society of Laparoendoscopic Surgeons’ annual meeting …

TransEnterix’s New Surgical Platform Recognized as ‘Innovation of the Year’ by the Society of Laparoendoscopic Surgeons

“Since TransEnterix’s start, we have collaborated closely with nationally renowned physicians to create a platform that will completely change minimally invasive abdominal surgery as we know it.” Todd M. Pope, President, CEO TransEnterix, Inc. RESEARCH TRIANGLE PARK, N.C. – (September 10, 2009) TransEnterix’s revolutionary laparoscopic surgical platform that allows surgeons to perform minimally invasive abdominal procedures entirely through the umbilicus, …

TransEnterix Inc Names Experienced Medical Device Executive Todd M. Pope As President, CEO

We believe our company is poised to experience tremendous growth for years to come and I am excited to have the opportunity to lead TransEnterix from its earliest stages.” Todd M. Pope, President, CEO TransEnterix, Inc. RESEARCH TRIANGLE PARK, N.C. (September 24, 2008) TransEnterix, an early-stage, privately-held medical device company focused on advanced minimally invasive surgery, announced today that the …

Synergy Life Science Partners Closes $143M Debut Medical Device Fund

Our goal is to help dramatically improve the standard of patient care in our therapeutic categories, while generating exceptional returns to the customers of and investors in our portfolio companies. John Onopchenko, Managing Director, Synergy Life Science Partners PORTOLA VALLEY, CA (January 8, 2008)…Synergy Life Science Partners, LP, a venture capital limited partnership focused on investments in emerging medical device …

TransEnterix™ Secures $21 Million in First Round of Institutional Financing

We are pleased to have such high-quality investors involved with us on TransEnterix. With this capital and these investors, we now look forward to the work in delivery of our innovative product platforms. Bill Starling, CEO, Synecor, Interim CEO, TransEnterix RESEARCH TRIANGLE PARK, N.C. (December 31, 2007) Synecor, LLC and SV Life Science Advisers, LLC announce today the first round …

R. Frederick McCoy, Jr. Appointed As Vice-Chairman Of The Board Of Directors Of Synecor, LLC

Synecor has attracted people and developed methods that are exceptional towards meaningful innovation in medical technology. R. Frederick McCoy, Jr., Vice-Chairman, Synecor Board of Directors RESEARCH TRIANGLE PARK, N.C. (July 17, 2007) Synecor, LLC, a privately held business generator with a history of innovating disruptive medical technologies in immense life science markets for the foundation of new company creation, today …

InnerPulse™ Secures $50 Million In New Equity Financing

This funding will allow our company the ability to commercialize a technology that will save the lives of many individuals with heart disease. Daniel A. Pelak, President and Chief Executive Officern, InnerPulse, Inc. RESEARCH TRIANGLE PARK, NC (January 29, 2007). . . InnerPulse, Inc, a privately held company developing unique technologies for the treatment of abnormal heart rhythms, announced today …

Interventional Rhythm Management Changes Name To InnerPulse And Announces A Move To A New Expanded Office, Lab, Manufacturing Facility

We believe our life-saving PICD device is a revolutionary technology that will redefine how we treat patients at risk of Sudden Cardiac Death and save thousands of lives of patients with heart rhythm disorders each year. Daniel A. Pelak, President and Chief Executive Officern, InnerPulse, Inc. RESEARCH TRIANGLE PARK, NC (June 26, 2006). . . InnerPulse, Inc, a privately held …

Interventional Rhythm Management, Inc. Secures $20 Million in Series B Financing

Research Triangle Park, NC – May 12, 2005 – IRM, Inc., an early stage cardiology company dedicated to the management of patients with cardiac arrhythmias and heart failure, announced today that it has raised $20 Million in Series B Financing. The financing included new investor Johnson & Johnson Development Corporation (JJDC) in addition to previous investors. IRM was founded in …

BaroSense, Inc. Secures $10 million in Series B Financing

BaroSense is dedicated to providing a safe, effective, and minimally invasive treatment as a new, successful weapon in the battle against obesity. Dan Balbierz, GM & VP of R&D, BaroSense, Inc. David E. Goodman, M.D. Appointed As President And Chief Executive Officer of BaroSense, Inc. Menlo Park, CA – January 31, 2005 – BaroSense Inc., a privately-held medical device company …

Guidant Completes Acquisition of Bioabsorbable Stent Company

Guidant’s bioabsorbable stent program is aligned with our strategy of leveraging bioabsorbable technologies to provide innovative site-specific therapy for the treatment of heart disease. Dana G. Mead, Jr., President, Vascular Intervention, Guidant Corporation INDIANAPOLIS, Ind. & SANTA CLARA, Calif.–(BUSINESS WIRE)–April 20, 2004–Guidant Corporation (NYSE:GDT – News) today announced the $6 million purchase of the remaining stake in a company developing …

IRM, Inc., a Synecor LLC Portfolio Company, Raises $15.1 Million in Series A Financing

IRM, Inc. is the synergistic result of our focus on major unmet patient clinical needs, market opportunity, and innovative medical device technology. Richard S. Stack MD, Managing Director of Synecor, LLC Research Triangle Park, NC – December 18, 2003 – IRM, Inc., an early stage cardiology company dedicated to the management of patients with cardiac arrhythmias and heart failure, announced …

Interventional Rhythm Management, Inc. Announces its Revolutionary Technology Platform for Cardiac Electrophysiology Devices

The IRM IID™ represents a major breakthrough technology for the significantly underserved patient population of defibrillator candidates. Richard S. Stack MD, President, IRM Fundamental Patent Application Published December 4th, 2004. Research Triangle Park, NC – January 12, 2005 – Interventional Rhythm Management Inc. today announces its revolutionary design for cardiac electrophysiology devices, such as implantable defibrillators and pacemakers. IRM’s ground-breaking …

BaroSense, Inc. Raises $6.2 million in Series A Round

We are pleased to be partnering with the thought leaders in bariatric surgery, gastroenterology, and endocrinology … to develop devices to treat obesity. Nathan Every, M.D. Menlo Park, CA and Research Triangle Park, NC – September 20, 2002 – BaroSense Inc., a medical device company specializing in the minimally invasive treatment of obesity, announces that it has secured $6.2 million …

Article: Growing Companies – Part II [excerpt from Start-Up, January 2002]

These are things that are going to change the way medicine is practiced! Richard S. Stack MD, Managing Director of Synecor LLC Incubators are hot and as their numbers multiply, so do the number of different models and approaches that these development partners take. The second of a two-part series. [download_link link=”https://www.synecor.com/news/Start_Up_Article.pdf”]Full Story PDF[/download_link]

Guidant, GE, and Duke University Take Stake in SyneCor, LLC

This is a groundbreaking partnership that allows each of our major investors a first look at cutting-edge health sciences technologies. Bill Starling, Managing Director of Synecor, LLC Menlo Park, Calif. – Dec. 12, 2000 – SyneCor, LLC, an accelerator company for new cardiovascular research, devices and development businesses, today announced that it has secured financing led by Frazier Healthcare and …